Third Culture Capital, LLC

What Third Culture Capital, LLC does

Third Culture Capital, LLC (3CC) is an early-stage healthcare venture capital firm founded in 2021 by Dr. Julien L. Pham, MD, MPH, and headquartered in Boston. The firm invests at pre-seed, seed, and Series A stages in companies that operate at the confluence of healthcare systems, technology, and access, applying a proprietary evaluation framework grounded in the Quintuple Aim (population health, care experience, provider well-being, per-capita cost reduction, and health equity) and the Third Culture Mindset founder-screening lens that identifies cross-disciplinary, systems-fluent builders.

Fund 1 is fully deployed across 16 portfolio companies spanning telehealth (SimpliFed, Mahmee, Zuri Fertility), AI-enabled analytics (IntusCare, KeyWise, Lime Health, ViTAA Medical Solutions), accessible speech technology (Voiceitt), biotech (Pragma Bio, Aviwell, AcousticaBio), and healthcare fintech (Binkey, Helm Health, Ciba Health). The portfolio's product surface collectively covers text, audio, image, structured-data, and multimodal AI, though 3CC itself does not build or operate AI systems. Notable capital events include a $4.7M Voiceitt seed round co-invested with Cisco Investments in December 2022 and a March 2023 Ciba Health round led by 3CC.

The firm generates revenue through conventional venture fund economics — management fees on committed capital and carried interest on exits — anchored by Dr. Pham's prior operating record (RubiconMD, $190M exit in 2021; Genprex NASDAQ IPO in 2018). Deal flow is sourced primarily through network-based inbound from Harvard Innovation Labs, Mass General Brigham, and Boston healthcare networks, supplemented by content marketing via a monthly Mailchimp newsletter and selective conference participation (e.g., HLTH). 3CC does not publicly disclose AUM, LP composition, fund size, or revenue figures.

Name

Third Culture Capital, LLC

Legal name

Third Culture Capital

Website

https://thirdculturecapital.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Third Culture Capital is a Boston-based, physician-led early-stage venture capital firm that invests in healthcare startups at pre-seed through Series A stages, evaluating founders against the Quintuple Aim thesis across a deployed portfolio of 16 companies.

Ownership category

akta.pro rank

Product category

Early-Stage Healthcare Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

akta.pro secondary industries

Emerging Manager / Seeding Platforms (Multi-Manager) (FSANAGAF), Venture Capital Fundraising Placement (FSAEALAC)

Keywords

• Venture capital
• Healthcare investing
• Early-stage funding
• Digital health
• Biotech investment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Fund Management: Third Culture Capital manages a venture capital fund (Fund 1) that has been fully deployed. The firm generates returns through equity investments in early-stage healthcare companies, with revenue realized through portfolio company exits, IPOs, and acquisitions. Notable prior exits include RubiconMD ($190M, 2021) and Genprex NASDAQ IPO (2018) attributed to the founding partner.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Third Culture Capital manages an early-stage venture capital fund (Fund 1, fully deployed) that makes equity investments in pre-seed through Series A healthcare startups. Investments target founders operating at the confluence of healthcare systems, technology, and access, with each deal evaluated against the Quintuple Aim framework. The firm also produces a bimonthly healthcare-insights newsletter distributed via Mailchimp.

Product overview

Third Culture Capital is an early-stage venture capital firm operating a single investment fund (Fund 1, fully deployed). The firm's primary offering is its investment platform aligned with the Quintuple Aim framework, supporting founders who operate at the intersection of healthcare systems, technology, and access. The fund's portfolio includes 16 portfolio companies spanning telehealth (SimpliFed, Mahmee, Zuri Fertility), AI-powered analytics (IntusCare, KeyWise, Lime Health, ViTAA Medical Solutions), clinical technology (Voiceitt, AcousticaBio), biotech/pharma (Pragma Bio, Aviwell), and healthcare fintech (Binkey, Helm Health, Ciba Health). The firm also publishes a monthly newsletter (3CC Newsletter) distributed via Mailchimp. Rather than a unified product platform, 3CC functions as a fund manager with a portfolio of healthcare technology investments.

Differentiator

Problem solved

Functional benefit

Products and services

• Third Culture Capital Fund (Fund 1) Early-stage venture capital fund making equity investments in pre-seed, seed, and Series A healthcare startups operating at the confluence of healthcare systems, technology, and access; each investment is evaluated against the Quintuple Aim framework. Capital is offered to founders of digital health, telehealth, AI-enabled clinical analytics, biotech, drug delivery, and health-fintech companies.
• 3CC Newsletter Bimonthly email newsletter distributed via Mailchimp covering healthcare innovation insights, portfolio company updates, and perspectives from the 3CC network; available to founders, LPs, and healthcare ecosystem followers.

Quantifiable outcome

• $190M exit (RubiconMD, 2021)
• +2 more outcomes

Named customers14 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature2 records

Partnerships

Two partnerships are on record, tiered core and notable.

• Harvard Innovation LabscoreStrategic or Co-development PartnerDr. Julien L. Pham serves as Senior Advisor for Healthcare and Life Sciences at the Harvard iLab. This advisory role provides 3CC with deep ecosystem access through Harvard and enables portfolio companies to leverage relationships within the Boston healthcare and innovation community.
• Mass General BrighamnotableStrategic or Co-development PartnerDr. Pham founded RHINNO Labs at Mass General Brigham, one of the first hospital-based healthcare innovation labs in the country. This prior institutional affiliation provides ongoing relationships and credibility within the Mass General Brigham ecosystem.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Optum Ventures: Optum Ventures is the corporate venture capital arm of Optum/UnitedHealth Group, investing in early- to growth-stage healthcare technology and services companies. It is comparable as a healthcare-dedicated VC, although with corporate strategic capital and a broader stage focus than 3CC.
• General Catalyst: General Catalyst is a multi-stage venture firm with a dedicated Health Assurance thesis investing across healthcare technology, services, and biotech. It is comparable as an early-stage healthcare-active investor with materially larger fund sizes and broader stage reach than 3CC.
• Bessemer Venture Partners (BVP): Bessemer Venture Partners is a multi-stage firm with a long-standing healthcare practice (BVP Rise) investing across healthcare technology, services, and biotech. It is comparable as a major healthcare-active investor, though at significantly larger fund sizes and broader sector exposure than 3CC.
• Andreessen Horowitz (a16z Bio/Health): Andreessen Horowitz operates dedicated healthcare and bio funds investing across stages in healthcare technology, digital health, and biotech. It is comparable as a healthcare-active investor with broader portfolio scope and significantly larger fund sizes than 3CC's emerging single-fund model.

Direct peers

• Rock Health: Rock Health is a venture fund and advisory firm focused exclusively on digital health, investing at seed through Series B in startups transforming care delivery. It is directly comparable to 3CC as a dedicated early-stage digital health investor with a thesis-driven, founder-support model.
• Flare Capital Partners: Flare Capital Partners is an early-stage healthcare-focused VC firm that backs founders building at the intersection of healthcare technology, services, and infrastructure. It is directly comparable to 3CC in stage focus (seed/Series A), healthcare vertical specialization, and value-add model built on deep operating expertise.
• Define Ventures: Define Ventures is an early-stage venture capital firm investing exclusively in health tech, with a network-driven model and focus on founders reimagining healthcare. It is directly comparable to 3CC in stage (seed/Series A), healthcare-only thesis, and ecosystem-driven deal sourcing.

Emerging players

• Maverick Ventures: Maverick Ventures is an early-stage venture capital firm investing across categories including digital health. It is comparable as a smaller, multi-stage fund with selective healthcare exposure, although it is not healthcare-exclusive like 3CC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thirdculturecapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Third Culture Capital, LLC